Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00640289
Other study ID # BB-IND5986
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2000
Est. completion date December 2011

Study information

Verified date March 2008
Source Children’s Hospital of Orange County
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Congenital deficiency of Factor XIII is a rare but potentially life threatening disorder. It is inherited in an autosomal recessive fashion. Infusion of Factor XIII has proved to be useful for prevention and treatment of bleeding episodes, especially of spontaneous intracranial bleedings. In this study, Fibrogammin P will be given to patients with congenital Factor XIII deficiency and congenital/acquired FXIII deficiency to prevent bleeding and to treat established bleeding episodes. For Factor XIII prophylaxis to prevent hemorrhages, the dosage will depend on the weight of the subject. The frequency of Factor XIII administration will be determined by the factor's circulating half-life. During the first month only, a Factor XIII pharmacokinetic study will be determined over a 4-week period. Safety data will include accrual of information on viral safety, liver function, complete blood counts and adverse events. Historical data concerning spontaneous bleeds will be collected whenever possible two years prior to treatment with Fibrogammin P.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients may be of either sex or age. Children and newborn infants are specifically included in this study.

- Patient must have documented congenital Factor XIII deficiency

- Patient or legal guardian must sign informed consent

- Patients who have negative serology for hepatitis B should receive Hepatitis B vaccination.

Exclusion Criteria:

- Patient has acquired Factor XIII deficiency

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fibrogammin P
Prophylaxis treatment

Locations

Country Name City State
United States Children's Hospital of Orange Co. Orange California

Sponsors (2)

Lead Sponsor Collaborator
Children’s Hospital of Orange County CSL Behring

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions Response is defined as: Excellent/Good = adequate hemostasis, similar to that expected for subjects without known bleeding disorders; Fair/Poor = hemostasis less than expected; None = severe bleeding, judged due to disease despite Factor XIII (FXIII) therapy. Only the subjects who needed additional FXIII infusions (apart from the prophylactic treatment) to control a bleed and who had investigator assessment of efficacy were counted in this outcome. Within 12 hours of FXIII infusion
Secondary Surgical Efficacy Assessments With Factor XIII Surgical efficacy is defined as: Excellent/Good = adequate hemostasis, similar to that expected for subjects without known bleeding disorders; Fair/Poor = hemostasis less than expected; None = severe bleeding, judged due to disease despite Factor XIII (FXIII) therapy. Only the subjects who underwent a surgical procedure were counted in this outcome measure. During surgical procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05617209 - In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Completed NCT05039008 - Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy N/A
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02546622 - ATHN 2: Factor Switching Study
Terminated NCT02586012 - Weight-based Dosing in Hemophilia A Phase 2
Completed NCT02165462 - Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy N/A
Unknown status NCT02433782 - Myofascial Therapy in Patients With Hemophilic Arthropathy N/A
Unknown status NCT02165592 - Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia N/A
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT05104164 - Self-myofascial Release in Hemophilic Ankle Arthropathy N/A
Terminated NCT01191372 - First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients Phase 1
Completed NCT05173129 - Posture Analysis for Patients With Haemophilia N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Withdrawn NCT03996486 - Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia Phase 1
Completed NCT03842605 - Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia N/A
Completed NCT01708564 - A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B Phase 1
Completed NCT05549843 - Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle N/A
Recruiting NCT06010953 - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment Phase 1/Phase 2
Completed NCT05027230 - A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor Phase 1/Phase 2
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease